Swedish biotech company Akiram Therapeutics has announced significant progress in its first clinical trial of AKIR001, a radiopharmaceutical intended to treat aggressive solid tumours. The company confirmed completion of the first patient cohort in its phase 1 study, with no safety concerns reported, allowing the trial to continue to its next stage. The study is […]